MyFiziq integrates with Apple HealthKit in ground-breaking development

|

Published 01-SEP-2020 11:01 A.M.

|

4 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Just 24 hours after MyFiziq Limited (ASX: MYQ) announced that it had made a transformational change to its on-device capabilities, the company has informed the market that it has completed a successful integration into the Apple HealthKit with all dimensional captures from MyFiziq’s technology.

Yesterday’s news drove the company’s shares up roughly 20% to 47.5 cents, a level it hasn’t traded at for more than two years.

These most recent developments could be the catalyst for further upside.

MyFiziq has developed and patented a proprietary body measurement dimensioning technology that enables its users to check, track and assess their dimensions using only a smartphone privately and accurately.

MyFiziq said today that it has successfully completed the integration and sharing of all data captured through its platform into the MyFiziq and CompleteScan application with the Apple HealthKit environment.

The group’s technology leverages the power of computer vision machine learning and patented algorithms to process images on secure, enterprise-level infrastructure, delivering an end-to-end experience that is unrivalled in the industry.

MyFiziq enables partner apps to extend Apple Health possibilities

Apple Health is the central repository for all health and fitness data on iOS.

Since its launch in 2014, iOS users have been able to configure and prioritise their applications and accessories to send the data that matters to their lifestyle and fitness goals to the Apple Health app.

From this aggregated data, Apple is able to summarise health information related to activity, nutrition and various other health related metrics.

Where information is not available via an app or accessory such as the Apple Watch, users also have the ability to manually update their data.

Now, with its latest release, MyFiziq can enable its partners to augment their current shareable data beyond just activity, removing the need for users to manually track their body circumference and composition measurements.

MyFiziq has achieved this by including a means to share anthropometric and body composition measures including body fat percentage, lean body mass, and waist circumference directly from a partner's app into Apple Health.

With Apple Health's API allowing a user to grant both ‘read and write’ access to their data, partner applications will be provided the opportunity to aggregate and interpret insights that previously would have been unattainable.

Facilitates correlation of data with World Health Organisation

The combination of activity, nutrition, body measurements and cardiovascular data will open up new opportunities for partners to correlate datasets with major health organisations.

Data comparison with the World Health Organisation, the International Diabetes Federation and other world renowned health organisations will assist in offering holistic health experiences that can be used to generate new health awareness opportunities whilst also helping with user-bases’ health.

For example, waist circumference could be combined with activity and nutrition data to show potential risks of type 2 diabetes, dyslipidaemia, hypertension or cardiovascular disease.

Furthermore, the addition of Nuralogix's facial scan as part of MyFiziq’s CompleteScan application will further extend the offering to be able to capture heart rate, heart rate variability and blood pressure, thereby unlocking additional insights and potential risks.

MyFiziq will be working with its partners as they leverage the possibilities of Apple's Health ecosystem, and management will now commence subsequent integrations with Google Fit and Samsung Health.

Understanding Apple HealthKit highlights upside for MyFiziq

HealthKit provides a central repository for health and fitness data on iPhone and Apple Watch.

With the user's permission, apps communicate with the HealthKit store to access and share this data, as well as collecting and storing health and fitness data.

The platform allows the user to analyse and visualise the data, with the opportunity to also share it through social interactions.

The Health app gathers health data from your iPhone, Apple Watch, and iOS platform apps that users already have access to, allowing them to view progress in one convenient place.

The Health app automatically counts steps, walking and running distances, and the Apple Watch automatically tracks your activity data.

As an all-encompassing platform, the Health app gathers information from the user’s iPhone, Apple Watch and third-party apps to quantify data about the user and their environment, displaying it in an easy-to-read, secure and accurate dashboard.

HealthKit is the developer framework behind it that allows apps to work with Apple Health and each other.

Consequently, this is an extremely material development for MyFiziq and its partners who will now be able to converge all of the data with the Apple HealthKit to draw on the central repository to provide better insight and engagement with their users.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X